Sofie Hallager1, Peer Brehm Christensen2, Steen Ladelund3, Mette Rye Clausen4, Alex Lund Laursen5, Axel Møller6, Poul Schlicthting7, Lone Galmstrup Madsen8, Jan Gerstoft9, Suzanne Lunding10, Karin Elmegaard Grønbæk11, Henrik Bygum Krarup12, Nina Weis13. 1. Department of Infectious Diseases. 2. Odense University Hospital, Department of Infectious Diseases, and Clinical Institute, University of Southern Denmark. 3. Clinical Research Center, and. 4. Departments of Hepatology. 5. Department of Infectious Diseases, Aarhus University Hospital, Skejby. 6. Department of Internal Medicine, Kolding Hospital. 7. Department of Gastroenterology, Copenhagen University Hospital, Herlev. 8. Department of Internal Medicine, Zealand University Hospital, Køge, Denmark. 9. Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, and. 10. Department of Lung Medicine and Infectious Diseases, Nordsjællands Hospital, Hillerød. 11. Department of Gastroenterology, Copenhagen University Hospital, Hvidovre. 12. Clinical Biochemistry and Department of Gastroenterology, Section of Molecular Diagnostics, Aalborg University Hospital,Denmark. 13. Faculty of Health and Medical Sciences, Department of Clinical Medicine, University of Copenhagen.
Abstract
BACKGROUND: Knowledge about mortality rates (MRs) in patients with chronic hepatitis C (CHC) with cirrhosis is limited. This study aimed to estimate all-cause MRs among patients with CHC with or without cirrhosis in Denmark compared with the general population. METHODS: Patients registered in the Danish Database for Hepatitis B and C with CHC and a liver fibrosis assessment were eligible for inclusion. Liver fibrosis was assessed by means of liver biopsy, transient elastography, and clinical cirrhosis. Up to 20 sex- and age-matched individuals per patient were identified in the general population. Data were extracted from nationwide registries. RESULTS: A total of 3410 patients with CHC (1014 with cirrhosis), and 67 315 matched individuals were included. Adjusted MR ratios (MRRs) between patients with or without cirrhosis and their comparison cohorts were 5.64 (95% confidence interval [CI], 4.76-6.67) and 1.94 (1.55-2.42), respectively. Cirrhosis among patients was associated with an MRR of 4.03 (95% CI, 3.43-4.72). A cure for CHC was associated with an MRR of 0.64 (95% CI, 0.40-1.01) among cirrhotic patients and 2.33 (1.47-3.67) compared with the general population. CONCLUSIONS: MRs were high among patients with CHC with or without cirrhosis compared with the general population. Curing CHC was associated with a reduction in MR among cirrhotic patients, but the MR remained higher than the general population.
BACKGROUND: Knowledge about mortality rates (MRs) in patients with chronic hepatitis C (CHC) with cirrhosis is limited. This study aimed to estimate all-cause MRs among patients with CHC with or without cirrhosis in Denmark compared with the general population. METHODS: Patients registered in the Danish Database for Hepatitis B and C with CHC and a liver fibrosis assessment were eligible for inclusion. Liver fibrosis was assessed by means of liver biopsy, transient elastography, and clinical cirrhosis. Up to 20 sex- and age-matched individuals per patient were identified in the general population. Data were extracted from nationwide registries. RESULTS: A total of 3410 patients with CHC (1014 with cirrhosis), and 67 315 matched individuals were included. Adjusted MR ratios (MRRs) between patients with or without cirrhosis and their comparison cohorts were 5.64 (95% confidence interval [CI], 4.76-6.67) and 1.94 (1.55-2.42), respectively. Cirrhosis among patients was associated with an MRR of 4.03 (95% CI, 3.43-4.72). A cure for CHC was associated with an MRR of 0.64 (95% CI, 0.40-1.01) among cirrhotic patients and 2.33 (1.47-3.67) compared with the general population. CONCLUSIONS: MRs were high among patients with CHC with or without cirrhosis compared with the general population. Curing CHC was associated with a reduction in MR among cirrhotic patients, but the MR remained higher than the general population.
Authors: Donghee Kim; Andrew A Li; Brandon J Perumpail; Chiranjeevi Gadiparthi; Won Kim; George Cholankeril; Jeffrey S Glenn; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed Journal: Hepatology Date: 2019-02-11 Impact factor: 17.425
Authors: Melissa Louise Kelly; Stephen M Riordan; Rohan Bopage; Andrew R Lloyd; Jeffrey John Post Journal: PLoS One Date: 2018-02-13 Impact factor: 3.240
Authors: Tangui Barré; Fabienne Marcellin; Vincent Di Beo; Jessica Delorme; Teresa Rojas Rojas; Philippe Mathurin; Camelia Protopopescu; François Bailly; Marion Coste; Nicolas Authier; Maria Patrizia Carrieri; Benjamin Rolland Journal: Addiction Date: 2019-11-20 Impact factor: 6.526